Alix Ventures
Alix Ventures is a San Francisco-based venture capital firm established in 2019, focused on early-stage life science startups. The firm is dedicated to supporting innovative companies that aim to make significant advancements in human health through the integration of technology and biology. Alix Ventures emphasizes the importance of partnering with passionate and experienced founders who possess unique insights to tackle pressing challenges in the life sciences sector. The team comprises seasoned entrepreneurs with backgrounds in venture capital and extensive experience in raising capital, scaling operations, and navigating regulatory complexities. Additionally, the firm has assembled a scientific and medical advisory board of accomplished PhD founders to enhance technical and clinical diligence. Alix Ventures prioritizes the success of its portfolio companies by offering a comprehensive platform of resources, including support for customer introductions, fundraising, and team building, while leveraging a robust network of industry executives from top pharmaceutical companies and health systems.
15 past transactions
Galatea Bio
Venture Round in 2025
Galatea Bio is a biotechnology company based in the United States, founded by Carlos Bustamante, Nicholas Katsanis, and Alexander Ioannidis. The company focuses on improving diagnostic testing and accelerating drug discovery specifically for diverse and underserved populations that have historically been underrepresented in genetics research. Galatea Bio operates a biobank that serves as a biosample and bioinformatics platform, utilizing advanced algorithms and innovative analyses to facilitate genomic discoveries. Through its world-class clinical network, the company aims to identify patients at risk for severe multi-inflammatory syndromes or infections, ultimately working to develop new tests, treatments, and cures that enhance healthcare outcomes for all.
Elegen
Series B in 2024
Founded in 2017 by Dr. Matthew Hill, Elegen is a biotechnology company specializing in microfluidic technology for the development of advanced DNA synthesizers. Its mission is to accelerate biomedical progress through innovative synthetic biology solutions.
Zafrens
Series A in 2023
Founded in 2021, Zafrens is a San Diego-based drug discovery company specializing in life sciences products. Its platform generates insights at the intersection of biology, chemistry, and engineering by directly mapping molecular states of single cells.
Chemify
Series A in 2023
Chemify specializes in developing a chemical digitization platform designed to facilitate drug and materials discovery as well as chemical synthesis. The company's innovative approach involves using automated synthetic hardware combined with digital XDL code to convert code into molecules on demand. This system is modular, universal, scalable, and teachable, making it highly versatile for various applications in chemical and material research. Chemify's software includes a unique chemical programming language and natural language recognition capabilities that translate synthetic procedures efficiently. Additionally, the platform features a comprehensive ontology that provides detailed insights into reaction conditions and flags potential issues, offering scientists real-time telemetry of reactions.
Xilis
Series A in 2022
Xilis, Inc. is a biotechnology company founded in 2019 and based in Chapel Hill, North Carolina. The company specializes in developing next-generation organoid technologies aimed at guiding precision therapy for cancer patients and enhancing drug discovery processes. Its flagship platform, XilisµO, facilitates rapid diagnostics, personalized drug screening, and the creation of scalable patient-derived models, which support high-throughput drug discovery. By enabling both physicians and pharmaceutical companies to conduct tailored drug screenings, Xilis aims to lower costs and improve treatment outcomes for cancer patients.
Zafrens
Seed Round in 2021
Founded in 2021, Zafrens is a San Diego-based drug discovery company specializing in life sciences products. Its platform generates insights at the intersection of biology, chemistry, and engineering by directly mapping molecular states of single cells.
Pair Team
Seed Round in 2021
Pair Team provides healthcare coordination services focused on underserved and vulnerable communities. It deploys a dedicated, tech-enabled care team—including community health workers, registered nurses, and behavioral health clinicians—to offer personalized, holistic support to Medicaid and Medicare patients and other low-income individuals facing barriers to care such as transportation, housing and food insecurity, and limited mobile access. The company acts as an extension of safety-net primary care systems, helping them deliver patient-centered care while integrating with community-based organizations. It is building a care delivery platform to standardize clinical practices, streamline administrative tasks, and enable clinicians to spend more time with patients.
Elegen
Series A in 2021
Founded in 2017 by Dr. Matthew Hill, Elegen is a biotechnology company specializing in microfluidic technology for the development of advanced DNA synthesizers. Its mission is to accelerate biomedical progress through innovative synthetic biology solutions.
Zafrens
Pre Seed Round in 2021
Founded in 2021, Zafrens is a San Diego-based drug discovery company specializing in life sciences products. Its platform generates insights at the intersection of biology, chemistry, and engineering by directly mapping molecular states of single cells.
Teiko.bio
Venture Round in 2021
Founded in 2020, Teiko.bio is a Salt Lake City-based company that provides an immune profiling platform. This platform supports global clinical trials by offering blood preservation kits, cytometry panels, data reports, and tailored gating services. It enables clinicians to make informed decisions regarding patient response.
Xilis
Series A in 2021
Xilis, Inc. is a biotechnology company founded in 2019 and based in Chapel Hill, North Carolina. The company specializes in developing next-generation organoid technologies aimed at guiding precision therapy for cancer patients and enhancing drug discovery processes. Its flagship platform, XilisµO, facilitates rapid diagnostics, personalized drug screening, and the creation of scalable patient-derived models, which support high-throughput drug discovery. By enabling both physicians and pharmaceutical companies to conduct tailored drug screenings, Xilis aims to lower costs and improve treatment outcomes for cancer patients.
Elegen
Seed Round in 2020
Founded in 2017 by Dr. Matthew Hill, Elegen is a biotechnology company specializing in microfluidic technology for the development of advanced DNA synthesizers. Its mission is to accelerate biomedical progress through innovative synthetic biology solutions.
Xilis
Seed Round in 2020
Xilis, Inc. is a biotechnology company founded in 2019 and based in Chapel Hill, North Carolina. The company specializes in developing next-generation organoid technologies aimed at guiding precision therapy for cancer patients and enhancing drug discovery processes. Its flagship platform, XilisµO, facilitates rapid diagnostics, personalized drug screening, and the creation of scalable patient-derived models, which support high-throughput drug discovery. By enabling both physicians and pharmaceutical companies to conduct tailored drug screenings, Xilis aims to lower costs and improve treatment outcomes for cancer patients.
Circularis Biotechnologies
Seed Round in 2020
Circularis Biotechnologies, Inc. is a biotechnology company founded in 2014 and headquartered in Oakland, California. The company specializes in developing innovative methods to regulate gene expression, which enhances the production yields of biotherapeutics. Circularis offers a range of products, including RACRE Variant Libraries, hCMV Variant Library, Protein expression with CMV promoters, and T7 Variant Library. In addition, it provides various services such as RACRE Enhancement, RACRE Discovery, RACRE Technology Access Program, and Ribozyme Analysis of Cis-Regulatory Elements. Through its advanced technologies and services, Circularis aims to improve the efficiency and effectiveness of biotherapeutic production.
Pair Team
Seed Round in 2019
Pair Team provides healthcare coordination services focused on underserved and vulnerable communities. It deploys a dedicated, tech-enabled care team—including community health workers, registered nurses, and behavioral health clinicians—to offer personalized, holistic support to Medicaid and Medicare patients and other low-income individuals facing barriers to care such as transportation, housing and food insecurity, and limited mobile access. The company acts as an extension of safety-net primary care systems, helping them deliver patient-centered care while integrating with community-based organizations. It is building a care delivery platform to standardize clinical practices, streamline administrative tasks, and enable clinicians to spend more time with patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.